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Type I diabetes (T1D) is a T cell-driven autoimmune disease that results in the killing
of pancreatic β-cells and, consequently, loss of insulin production. Using the multiple
low-dose streptozotocin (MLD-STZ) model of experimental autoimmune diabetes, we
previously reported that pretreatment with a specific acetylcholinesterase inhibitor
(AChEI), paraoxon, prevented the development of hyperglycemia in C57BL/6 mice. This
correlated with an inhibition of T cell infiltration into the pancreatic islets and a reduction in
pro-inflammatory cytokines. The cholinergic anti-inflammatory pathway utilizes nicotinic
and muscarinic acetylcholine receptors (nAChRs and mAChRs, respectively) expressed
on a variety of cell types. In this study, we carried out a comparative analysis of the
effect of specific antagonists of nAChRs or mAChRs on the development of autoimmune
diabetes. Co-administration of mecamylamine, a non-selective antagonist of nAChRs
maintained the protective effect of AChEI on the development of hyperglycemia. In
contrast, co-administration of atropine, a non-selective antagonist of mAChRs, mitigated
AChEI-mediated protection. Mice pretreated with mecamylamine had an improved
response in glucose tolerance test (GTT) than mice pretreated with atropine. These
differential effects of nAChR and mAChR antagonists correlated with the extent of islet
cell infiltration and with the structure and functionality of the β-cells. Taken together, our
data suggest that mAChRs are essential for the protective effect of cholinergic stimulation
in autoimmune diabetes.
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INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disease characterized by the progressive destruction
of the insulin-producing β-cells in the pancreatic islets of Langerhans by autoreactive T cells.
The development of the disease starts with the β-cell destruction in individuals with genetic
pre-disposition and under specific environmental factors, followed by recruitment and activation of
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inflammatory cells (T and B cells, myeloid, and natural killer
cells) to the islets leading to insulitis (1, 2).
The vagus nerve innervates the pancreas by the
intrapancreatic parasympathetic nerve endings where the
neurotransmitter, acetylcholine (ACh) is released. ACh, in
turn, can bind to the nAChRs and mAChRs expressed on
pancreatic cells and hence play a key role in regulating
pancreatic metabolic functions including glucose homeostasis
(3). Increased vagal activity induces insulin secretion by
acting on mAChRs expressed on the pancreatic β-cells
(4–8). Although β-cells seem to express several subtypes
of muscarinic receptors (9–11), M3 mAChR is the most
abundant on these cells (12–14) and the one that mediates
insulin release (15). Mice selectively lacking M3 mAChR in
pancreatic β-cells have an impaired glucose tolerance and
a significantly reduced insulin release. In contrast, mice
overexpressing pancreatic M3 mAChR exhibit an increase
in glucose tolerance and insulin secretion (16). There is
also evidence that pancreatic β-cells functionally express
different subunits (α4, α5, α7, and β2) of nAChRs (17)
but the involvement of these receptors in β-cell function is
still controversial. While some studies reported no effect of
nAChR agonists on hyperglycemia or β-cell function (17–19),
other studies showed that the administration of specific
α7nAChR agonists reduced hyperglycemia in diabetic animal
models (20–22).
The vagus nerve also serves as a link between the
central nervous system and the immune system through the
cholinergic anti-inflammatory pathway where ACh suppresses
the release of pro-inflammatory cytokines (TNFα, IL-6,
HMGB1), attenuating the inflammatory response in sepsis
and inflammatory diseases (23–27). Specifically, the α7nAChR
has been reported to have a critical role in the inhibition of
pro-inflammatory cytokine production by macrophages as well
as in other immune mechanisms like apoptosis of T cells and
suppressive function of T regulatory cells (28). Furthermore,
the presence of a cholinergic system in non-neuronal cells,
including immunocompetent cells, has been extensively
demonstrated. These cells have choline acetyltransferase
(Chat) and acetylcholinesterase (AChE) enzymes as well
as choline transporters needed for ACh production (29).
Additionally, immune cells express both muscarinic and
nicotinic ACh receptors (26, 29–32), indicating that the
cholinergic system may be involved in the regulation of the
immune response. The α7nAChR is expressed on neutrophils,
macrophages, B and T cells, and dendritic cells as well as on
enterocytes, endothelial and microglial cells (26, 28, 33, 34),
and has been implicated in the pathogenesis of autoimmune
diseases (28).
We and others previously demonstrated that activation of
the cholinergic nervous system through the administration
Abbreviations: ACh, acetylcholine; AChE, acetylcholinesterase; AChEI,
acetylcholinesterase inhibitor; AChR, acetylcholine receptor; nAChR, nicotinic
acetylcholine receptor, mAChR, muscarinic acetylcholine receptor; MCA,
mecamylamine. An “∗” indicates a set of nAChR that contains the specified
subunit but it can contain additional unspecified subunits (35).
of specific acetylcholinesterase inhibitors (AChEI) attenuates
the development of hyperglycemia and experimental diabetes
(36, 37). In our model system, prophylactic cholinergic
stimulation induced by paraoxon, an irreversible AChEI,
prevented the incidence and development of STZ-mediated
hyperglycemia and type-1 diabetes in the multiple low-dose
streptozotocin (MLD-STZ) mouse model (36). This correlated
with a reduction in T cell infiltration into pancreatic islets,
preservation of the structure and functionality of β-cells, and
a reduction in pro-inflammatory cytokines. The present study
was designed to assess the effect of mAChRs and nAChRs
antagonists, mecamylamine hydrochloride and atropine,
respectively, on AChEI-mediated prevention of hyperglycemia
in the MLD-STZ model. Mecamylamine hydrochloride is a
non-selective antagonist of nAChRs (specially α3β4, α4β2, α3β2,
and α7) that binds non-competitively to the allosteric site of the
receptor and prevents its activation (38). At the neuromuscular
junction, mecamylamine is an open-channel blocker (39). At
low doses it is used for treatment of various neuro-psychiatric
disorders, while at higher doses is indicated for treatment of
severe hypertension (40). Atropine is a non-selective, clinically
relevant, antagonist of mAChRs that binds competitively
to the active site of the receptor without activating it, and
completely inhibits the M1, M2, M3, M4, and M5 ACh receptors.
Additionally, atropine can block nicotinic α9-containing AChRs
(α9∗nAChRs) (41). Both mecamylamine and atropine cross
the blood-brain barrier. Our results indicate that inhibition of
nAChR did not abolish the anti-diabetic effect of AChEI. In
contrast, inhibition of mAChRs largely reversed the beneficial
effect of paraoxon and was associated with increased islet cell
infiltration and β-cell damage. These findings suggest a model
in which mAChRs can influence the outcome of inflammatory
autoimmune diseases.
MATERIALS AND METHODS
Experimental Animals
C57BL/6 male mice were purchased from the Jackson Laboratory
(Bar Harbor, ME, USA) and bred in the animal facility of
the College of Medicine and Health Sciences, UAE University.
Female mice aged 8–10 weeks (weight range 20–22 g) were used
for the experiments. All studies involving animals were carried
out in accordance with, and after approval of the animal research
ethics committee of the College of Medicine and Health Sciences,
UAE University.
Chemicals
Paraoxon (Sigma, St. Louis, MO, USA), an organophosphorus
compound, is a highly specific, irreversible, inhibitor of AChE
(AChEI). The preparation for paraoxon administration has been
described in detail (42). A working solution for intraperitoneal
(i.p.) injection was prepared ex tempore in pyrogen-free saline
to a concentration of 80 nmol/ml. Each mouse received 40
nmol/day of AChEI or saline as control. Atropine sulfate (10
mg/kg) andmecamylamine hydrochloride (MCA; 2mg/kg), both
from Sigma, were injected i.p. 15min prior to paraxon injection
in a volume of 100 µl/day/mouse. These doses were chosen to be
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in the pharmacological range based on abundant evidence from
the literature (43–46). Streptozotozin (STZ; Sigma) was prepared
ex tempore in citrate buffer (pH 4.5) and used i.p. at 60mg/kg/day
per mouse.
Diabetes Induction
The protocol for diabetes induction has been described (36).
Mice received five daily doses of STZ; control mice received
citrate buffer. At different time points post-STZ administration,
blood was drawn from the tail vein to determine glucose levels
using One-Touch-ultra-strip (Lifescan, Zurich, Switzerland).
Hyperglycemia was defined as a non-fasting blood glucose level
of >200 mg/dl.
Experimental Protocol
Twenty-five age-matched mice were randomly assigned into
five groups (3–5 mice per group). Group I received daily i.p.
injection of sterile saline. Group II received daily injection of
AChEI. Group III received MCA and AChEI daily injections.
Group IV was daily injected with atropine and AChEI. All
treatments lasted for 3 weeks (5 day/week). Mice were weighed
weekly, at which time blood was collected and analyzed for
AChE activity. At the end of treatment, group I was divided
into 2 subgroups with 3–5 mice/group, A and B. Group IA
(Saline) received daily injections of citrate buffer while groups
IB (Saline+STZ), II (AChEI+STZ), III (MCA+AChEI+STZ),
and IV (Atropine+AChEI+STZ) received daily injection of
STZ for 5 consecutive days. Mice were followed for blood
glucose level for up to 60 days post-STZ administration at
which time they were sacrificed, and pancreatic tissue collected
for analysis.
AChE Activity of Red Blood Cells (RBC)
The detailed procedure for determining AChE enzyme activity
in RBC has been described (42, 47). Briefly, freshly drawn
venous blood samples were incubated with DTNB (10mM) and
ethopropazine (6mM) for 20min at 37◦C prior to addition of
acetylthiocholine. The change in the absorbance of DTNB was
measured at 436 nm. The AChE activity was calculated using
an absorption coefficient of TNB− at 436 nm (ε = 10.6 mM−1
cm1). The values were normalized to the hemoglobin (Hb)
content (determined as cyanmethemoglobin) and expressed as
mU/µM/Hb enzyme activities were expressed as percentage of
the baseline activity (100%).
Glucose Tolerance Test (GTT)
Mice were fasted for 16 h, but with free access to water.
Blood was obtained from the tail-vein and assessed for baseline
fasting glucose levels using a One-touch Ultra glucometer. Mice
were then weighed and received 2 g/kg body weight of glucose
by i.p. injection (30% glucose solution). Blood samples were
subsequently collected at 10, 20, 60, and 120min to determine
glucose levels.
Histology and Immunohistochemistry of
Pancreatic Tissue
The histological analysis of excised pancreatic tissue was
performed following a previously described protocol (48, 49).
Tissue sections were stained with haematoxylin and eosin (H&E)
and images were captured using Olympus BX51 microscope
equipped with digital camera DP26 (Tokyo, Japan). Indirect
immunostaining for insulin was performed using guinea pig
polyclonal antibody (Dako, Carpinteria, CA, USA) followed
by FITC-conjugated donkey anti-guinea pig IgG (Jackson
ImmunoResearch, West Grove, PA, USA). Slides were counter-
stained with propidium iodide (BD Biosciences, USA) and then
examined and photographed under a Nikon C1 laser scanning
confocal microscope.
Quantitative RT-PCR
qRT-PCR was carried out as previously described (50) on RNA
extracted from pancreatic tissue of each animal. After RNA
FIGURE 1 | Cholinergic pathway-induced anti-hyperglycemic effect is primarily mediated via mAChRs. Mice were pretreated with saline or paraoxon (AChEI) alone or
concurrently with atropine or mecamylamine for 3 weeks followed by STZ for five consecutive days (MLD-STZ). Blood glucose concentrations were measured at the
indicated time points. Mice with blood glucose levels >200 mg/dl were considered diabetic. Data are pooled from two independent experiments. The numbers in
parenthesis represent the total number of mice per group. For the statistical analysis, the two-way ANOVA with Tukey’s multiple comparisons post-test was used.
Asterisk denote significance between the saline/STZ group and the indicated experimental groups (*p ≤ 0.05, ***p ≤ 0.001).
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extraction and purification, cDNAwas synthesized using Taqman
reverse transcription reagents (Applied Biosystems, Foster City,
CA, USA) following manufacturer’s protocol. TaqMan primer
and probe were used to study the expression of insulin (Applied
Biosystems). Transcript levels of target gene were normalized
according to the dCq method to respective mRNA levels of the
housekeeping gene HPRT.
Statistical Analysis
Statistical significance between control and treated
groups was analyzed using the unpaired, two-tailed
Student’s t-test, using the statistical program of GraphPad
Prism version 6 software. For multiple comparisons,
we used two-way ANOVA with Tukey’s post-hoc test
(GraphPad Prism). Differences between experimental
groups were considered significant when P-values
were <0.05.
RESULTS
Cholinergic Pathway-Induced Protection Is
Mediated Primarily Via mAChRs
As reported earlier (36), MLD-STZ administration in saline-
pretreated mice induced progressive hyperglycemia that led
to the animals becoming diabetic by the second week of STZ
injection (Figure 1; Saline+STZ group). In contrast, paraoxon
pretreatment prevented the development of hyperglycemia
and diabetes in STZ-treated mice (AChEI+STZ group). When
the nAChR antagonist MCA was administered together with
paraoxon, transient elevation in blood glucose levels were
observed in 2 out of 6 mice on day 28 post STZ treatment
but these levels normalized thereafter (MCA+AChEI+STZ
group). In contrast, when the mAChR antagonist atropine
was co-administered with paraoxon, STZ treatment induced
a progressive increase in blood glucose averaging >200
mg/dl by day 28 post-STZ treatment. These elevated levels
persisted in 4 out of 6 mice in this group until the end of
the observation period (Figure 1; Atropine+AChEI+STZ
group). These results suggest that the mAChRs play
an important role in the AChEI-induced protection in
this model.
Mice in the different groups were subjected to the GTT to
evaluate their response to i.p. injected glucose (2 g/kg body
weight) following a fasting period of 16 h (Figure 2). Significantly
higher levels of blood glucose were observed in saline+STZ
group compared to saline control. In the saline control group,
the maximum glucose level was reached after 10min (268
mg/dl), sharply decreased by 20min (182 mg/dl), and gradually
normalized (102 mg/dl) by the end of the test (120min). In
contrast, STZ-treated mice reached a maximum level of 400
mg/dl after 20min and, despite slowly decreasing over time,
remained significantly elevated (237 mg/dl) at the end of the
test period.
Mice receiving paraoxon (AChEI)+STZ exhibited an almost
identical response in the IPGTT (intraperitoneal GTT) to
normal controls. Importantly, these results show that paraoxon
pretreatment not only prevented the development of diabetes but
also rendered the animals able to respond normally to high levels
of glucose.
In the experimental MCA+AChEI+STZ animal group,
blocking of nAChRs failed to alter the protective effect
of paraoxon as mice were able to control the increase
in blood glucose levels in a manner indistinguishable
from control mice. In sharp contrast, animals in the
atropine+AChEI+STZ group exhibited response kinetics
that were very similar to the saline+STZ group, indicating
that blocking of mAChRs mitigated the protection
afforded by paraoxon.
FIGURE 2 | AChEI improves glucose tolerance test (GTT). Animals were pretreated with saline or AChEI alone or concurrently with atropine or mecamylamine for 3
weeks followed by MLD-STZ. At day 56 post-STZ administration, GTT was performed and blood glucose response recorded. Data are shown as comparative
responses between saline controls, saline+STZ, AChEI+STZ, MCA+AChEI+STZ, and Atropine+AChEI+STZ treated mice. Values represent mean ± SEM of 6–10
mice per group from two independent experiments. The numbers in parenthesis represent the total number of mice per group. For the statistical analysis, the two-way
ANOVA with Tukey’s multiple comparisons post-test was used. Asterisk denote significance between the saline/STZ group and the indicated experimental groups (**p
≤ 0.01, ***p ≤ 0.001).
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FIGURE 3 | Insulin production is mostly modulated by muscarinic ACh receptors. Mice were treated with AChEI or saline for 3 weeks and then challenged with STZ.
At day 60 post STZ administration mice were sacrificed, pancreas excised, fixed, and stained with insulin-specific antibody. Light confocal micrographs of
insulin-expressing β-cells in pancreatic islets of mice treated with only saline (A,F), saline+STZ (B,G), AChEI+STZ (C,H), MCA+AChEI+STZ (D,I), and
Atropine+AChEI+STZ (E,J) are shown. Bars in the figures indicate 20µm (B,C,I,J), 32µm (A,F,G,H), and 60µm (D,E). Photos are representative of two individual
experiments (n = 4 mice/group).
Abrogation of ACh-Mediated Protection by
a Muscarinic Receptor Antagonist
Immunohistochemical analysis of insulin expression
was performed on pancreatic tissue at day 60 post-STZ
administration. Consistent with our previous findings
(36), STZ administration induced loss of insulin in the
islets of Langerhans in STZ-injected group (saline + STZ)
(Figures 3B,G) compared to normal controls (Figures 3A,F). In
contrast, paraoxon pre-treated mice (AChEI + STZ) exhibited
intact islets, well preserved from the destructive effect of STZ
on insulin producing cells (Figures 3C,H). When paraoxon
treatment was administered together with MCA to block
nAChRs (MCA+AChEI+STZ group), the protective effect
of paraoxon over the pancreatic β cells was mostly preserved
(Figures 3D,I). However, administration of paraoxon with
atropine (atropine+AChEI+STZ) led to a dramatic decrease
in insulin expression, indicating that blocking of the mAChRs
ameliorated the protective effect of AChEI on insulin production
in the islets (Figures 3E,J).
We also analyzed the insulin mRNA levels in pancreatic
tissue at day 60 post-STZ administration (Figure 4). STZ
treatment in saline group (saline+STZ) led to a 6.3-
fold reduction in the level of insulin mRNA relative to
control saline. Similar levels of insulin mRNA to the
saline control group were found in paraoxon pretreated
(AChEI+STZ) and MCA+AChEI+STZ groups. When atropine
was injected with the AChEI, a significant reduction in
the levels of insulin mRNA was observed, compared to
saline control group. It is worthy to note that although
no significant differences were obvious among the three
paraoxon treated groups, the levels of insulin mRNA were
higher in the MCA+AChEI+STZ than in AChEI+STZ and
Atropine+AChEI+STZ groups which could indicate the
FIGURE 4 | Insulin expression in pancreatic tissue. Mice were treated as
described in Figure 2 legend. At day 60 post STZ administration, pancreatic
tissue was obtained and processed for RNA extraction. mRNA expression of
pancreatic insulin was determined by qRT-PCR. The graph depicts values
from two independent experiments (n = 8–10 mice/group). Asterisks indicate
significance compared to the saline control group (*p ≤ 0.05, **p ≤ 0.01).
importance of the muscarinic ACh receptors in the production
of insulin.
Blockade of mAChRs Increases Cellular
Infiltration and Leads to Islet Destruction
Pancreatic tissue stained with hematoxylin and eosin was
analyzed at day 60 post-STZ administration. Saline control
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FIGURE 5 | Loss of islets morphology following blockade of mAChRs. H&E staining of paraffin embedded pancreata from mice sacrificed at day 60 post-STZ
administration. Five experimental groups are represented in this figure: saline (A,F), saline+STZ (B,G), AChEI+STZ (C,H), MCA+AChEI+STZ (D,I), and
Atropin+AChEI+STZ (E,J). Dashed lines delineate Langerhan’s islets and arrows indicate inflammatory infiltrates. Images are representative of two independent
experiments (n = 4 mice/group). The bar in the figures indicates 50µm (panels A–E) and 20µm (panels F–J). (K) Quantitative estimation of infiltrated islets.
H&E-stained pancreatic sections were examined to quantify the number of islets containing inflammatory cell infiltrates. The graph depicts values from two
independent experiments (n = 4 mice/group/experiment). Three sections per mouse were used for the quantification. Asterisks denote significance between the
indicated experimental groups (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). Asterisks on top of the bars indicate significance with the saline group.
mice had intact islets with no visible inflammatory infiltration
(Figures 5A,F). STZ administration to saline-pretreated mice
induced a massive infiltration of inflammatory cells that
disturbed the normal morphology of the islets (Figures 5B,G).
In contrast, paraoxon treatment prior to STZ administration
largely prevented any significant inflammatory cell infiltration
and showed intact islet morphology (Figures 5C,H). Likewise,
cotreatment of paraoxon and mecamylamine previous to STZ
administration prevented islet infiltration by inflammatory cells
and preserved their normal structure (Figures 5D,I). In contrast,
pretreatment with paraoxon and atropine led to extensive cellular
infiltration into the islets and destruction of normal morphology
(Figures 5E,J). It should be noted that in the latter group, a few
healthy islets could still be observed in some mice. These results
suggest that the presence of active mAChRs is essential to protect
β-cells against STZ-mediated destruction. It is worth noting
that mice treated with AChEI alone show no evidence of any
alterations in islet morphology or extent of cellular infiltration
(36) and, hence, this experimental group was not included in the
current study.
Next, we sought to quantitate the observed alterations in
islet morphology by determining the number of islets with
infiltrated cells (Figure 5K) in H&E stained-pancreatic sections
of each experimental group. Compared to saline controls, STZ
treatment resulted in highly infiltrated islets. Pretreatment with
AChEI led to a significant reduction (>65%) in the extent of
cellular infiltrates into the pancreatic islets, hence preserving islet
morphology. The number of islets with lymphoid infiltration
in the AChEI+MCA+STZ experimental group was comparable
to the AChEI+STZ group. However, blocking of the mAChRs
with atropine led to a significant increase in the number
of infiltrated islets to a level comparable to that observed
in the saline+STZ group, indicating the need for functional
mAChRs to avoid inflammation and, therefore, maintain healthy
insulin-producing β cells.
DISCUSSION
It is well-established that ACh regulates the endocrine function
of the pancreas and is essential to maintain glucose homeostasis.
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In rodent’s pancreas, the only source of ACh are the neural
terminals, in contrast to pancreas of humans where glucagon-
producing α-cells are able to produce ACh to modulate β-cell
function (3). It has been postulated that the development of
autoimmune diabetes (T1D) and other autoimmune diseases is
triggered by a dysfunction of the autonomic nervous system
(51–53) followed by recruitment of inflammatory cells (22).
Failure or insufficient efferent vagus nerve cholinergic output
might allow the overproduction of inflammatory cytokines and,
therefore, a dysfunctional immune and metabolic regulation that
in normal conditions would not occur (51, 52). Our previous
work demonstrated that increased cholinergic pathway activation
through a chronic administration of paraoxon, an irreversible
specific inhibitor of AChE, protected against development of
T1D in MLD-STZ mouse model (36). ACh signals through two
different types of receptor, muscarinic and nicotinic, both present
on pancreatic and immune cells. Our aim in this study was
to delineate the role of muscarinic (mAChRs) and nicotinic
(nAChRs) receptors in paraoxon-mediated protection using
two different receptor antagonists, namely mecamylamine and
atropine. Mecamylamine is a non-selective antagonist of nAChRs
that binds non-competitively to the allosteric site of the receptor
and prevents its activation. Atropine is an antagonist of mAChRs
that binds competitively to the active site of the receptor without
activating it. Both mecamylamine and atropine can also cross the
blood-brain barrier.
In this study, we demonstrate that co-treatment with AChEI
and mecamylamine did not abolish the protective effect of
AChEI on the development of STZ-mediated hyperglycemia.
In contrast, blocking of mAChRs with atropine reversed the
protective effect of paraoxon. These results correlated with the
immunohistochemical and insulin mRNA analysis of pancreatic
tissue where the concurrent administration of mecamylamine,
but not atropine, preserved insulin production in β-cells. The
fact that insulin production was decreased when mAChRs
were specifically inhibited suggests an important role for
these receptors in regulating insulin production. The results
of the GTT offer further confirmation for this conclusion.
Animals in the MCA+AChEI+STZ group, where mAChRs
were available, performed better than their counterparts treated
with atropine+AChEI+STZ, where mAChRs were blocked,
demonstrating the importance of the pancreatic islets’ cholinergic
innervation in the prevention of diabetes.
It is worth noting the existence of α9∗ nAChR, a special
member of AChRs with a mixed nicotinic and muscarinic
profile (41). Originally discovered in cochlear cells (54), α9∗
nAChRs are now known to be expressed on several cell
types including lymphoid and myeloid cells (55–57). The α9∗
nAChRs are blocked by nicotine (an agonist for the rest of the
subunits of nicotinic receptors) and by atropine, a non-selective
muscarinic receptor antagonist (41). The involvement of α9∗
nAChRs in inflammation has been highlighted by the findings
that mice genetically deficient in α9 subunit are protected
against the development of murine experimental autoimmune
encephalomyelitis, a model of multiple sclerosis (58). In the
current study, concurrent treatment with atropine plus AChEI
abrogated the latter’s protective effect against STZ-induced
hyperglycemia. This suggests the importance of muscarinic
receptors, α9∗ nAChRs or both in AChEI-mediated protection.
In contrast, administration of the general nAChRs antagonist
MCA (41, 59) had no effect on AChEI-mediated protection,
suggesting that nAChRs may not be important for the beneficial
effect. Overall, our findings suggest that muscarinic cholinergic
receptors play a predominant role in AChEI-mediated protection
in the MLD-STZ model.
STZ is known to induce apoptosis in insulin-producing β-
cells (60). Production of AChE by apoptotic cells (61, 62)
and the protective effect that AChE inhibitors exert against
FIGURE 6 | Proposed model for the effects of systemic acetylcholinesterase inhibition on pancreatic β cells and splenic lymphoid cells.
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apoptosis has been well-documented (63). Moreover, there is
evidence that ACh acts through mAChRs to protect neuronal
cells against apoptosis induced by different stimuli, including
pro-inflammaory cytokines and pro-apoptotic agents (64–66).
In our model system, paraoxon appears to counteract the
pro-apoptotic effect of STZ on β cells, hence inhibiting the
development of hyperglycemia and autoimmune diabetes (36).
The current findings implicate the mAChRs in this protection,
thus demonstrating for the first time the important role played
by these receptors in preserving β-cell function.
In summary, we have demonstrated that co-administration of
paraoxon and mAChR antagonist blocks the protective signaling
of ACh, suggesting a critical role for mAChRs in the protection
of β-cells against STZ-mediated death. It is also noteworthy
that signaling through mAChRs may act directly to stimulate
the secretion of insulin by β cells. Therefore, available evidence
suggests that signaling through mAChRs on β cells could act
via two different pathways to increase insulin secretion and
protect against apoptosis. Additionally, it is important to note
that the administration of muscarinic or nicotinic antagonists
may affect the receptors present in many different peripheral
tissues as well as the brain. The observed in vivo effects are
likely the result of the sum of multiple activities that involve
different tissues, including lymphoid cells. For example, the
cholinergic anti-inflammatory pathway, operating at the level of
the spleen through the nAChRs, may also limit the inflammatory
response in the islets. Although inflammation is considered as
a major pathogenic factor in diabetes and its complications, the
origin of this inflammation is still unclear (53). It is known that
the autonomic nervous system has a role in inflammation and
autoimmunity. The cholinergic anti-inflammatory pathway can
modulate the inflammatory response to infection and injury and
downregulate the production of inflammatory cytokines (24, 67).
In a study using NODmice, it was demonstrated that the neurons
innervating pancreatic β-cells were lost before any damage in the
islets could be detected (68). Therefore, our results are consistent
with the idea that a dysfunction of the autonomic nervous system
could be the initiating trigger in autoimmune diabetes.
We conclude that the effect of paraoxon treatment on the
development of hyperglycemia in theMLD-STZmodel is due to a
combination of factors: (a) stimulation of insulin production by
β-cells and (b) protection against STZ-induced apoptosis, both
through the mAChRs, and (c) differentiation of Th1 (T helper 1)
cells and mitigation against the development of pathogenic Th17
(T helper 17) cells (36). A diagram summarizing our findings
is shown in Figure 6. Our current experimental system could
be further probed using a combination of genetic (using M3
AChR-deficient mice) and pharmacologic (using selective M3
AChR antagonists, such as darifenacin) approaches to refine
our understanding of the role of the cholinergic pathway in
autoimmune diabetes.
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